BerandaPRE • NASDAQ
add
Prenetics Global Ltd
$4,42
Setelah Jam Perdagangan Normal:(5,20%)+0,23
$4,65
Tutup: 22 Nov, 20.00.00 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$4,61
Rentang hari
$4,42 - $4,42
Rentang tahun
$2,85 - $7,84
Kapitalisasi pasar
54,00Â jt USD
Volume Rata-Rata
11,72Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
NVDA
3,22%
0,35%
0,97%
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 5,94Â jt | 4,32% |
Biaya operasional | 14,38Â jt | 0,52% |
Laba bersih | -10,72Â jt | 50,83% |
Margin laba bersih | -180,46 | 52,87% |
Penghasilan per saham | — | — |
EBITDA | -9,51Â jt | 13,59% |
Tarif pajak efektif | 0,79% | — |
Neraca
Total aset
Total liabilitas
(USD) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 63,89Â jt | -67,46% |
Total aset | 233,31Â jt | -16,93% |
Total liabilitas | 42,30Â jt | -30,22% |
Total ekuitas | 191,00 jt | — |
Saham yang beredar | 12,22 jt | — |
Harga terhadap nilai buku | 0,30 | — |
Tingkat pengembalian aset | -11,12% | — |
Tingkat pengembalian modal | -13,33% | — |
Arus Kas
Perubahan kas bersih
(USD) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -10,72Â jt | 50,83% |
Kas dari operasi | — | — |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | — | — |
Arus kas bebas | — | — |
Tentang
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Didirikan
2014
Situs
Karyawan
322